Similarly, the synergistic effect of MEK and AKT inhibitors has been previously observed [32,34], and is currently investigated in clinical trials (including multiple myeloma, breast, endometrial, colorectal, non-small cell lung cancer, pancreatic cancer, ovarian cancer) [60]. This evidence concerns the gene AKT1 and plasma cell myeloma.